Drugs / MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells
MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells
also known as
IMA202
Cell therapy targets MAGEA1 via depletion
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04639245 | Jul 2021 → Aug 2022 | female breast carcinoma, metastatic malignant neoplasm, non-small cell lung carcinoma, triple-negative breast carcinoma +1 | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04639245 ↗ |
| Known as | IMA202 | “IMA202 consists of autologous genetically modified cytotoxic CD8+ T cells expressing a T cell receptor (TCR), which is specific for a nine amino acid peptide derived from MAGEA1.” PMID 39038917 ↗ Jul 2024 |
| Action | Deplete | “These MAGE-A1-specific T cells may help the body's immune system identify and kill MAGE-A1 tumor cells.” NCT04639245 ↗ |
| Modality | Cell therapy | “genetically engineered cells called FH-MagIC TCR-T cells” NCT04639245 ↗ |
| Target | MAGEA1 | “IMA202 consists of autologous genetically modified cytotoxic CD8+ T cells expressing a T cell receptor (TCR), which is specific for a nine amino acid peptide derived from MAGEA1.” PMID 39038917 ↗ Jul 2024 |